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1078Background: Controversy still exists about the superiority of the radial artery (RA) over the saphenous vein
graft (SVG) as a second conduit for surgical myocardial revascularization. We aimed to investigate the presence
of any survival benefit from use of the RA and relate it to patients’ age.
Methods: Propensity score matching was conducted on 9005 patients who underwent first-time isolated
coronary artery bypass grafting (CABG) using the left internal thoracic artery at a single institution from
1996 to 2012. The use of RA was recorded in 936 patients, whereas the use of SVGs only was recorded in
8069 patients. The primary study end point was all-cause death. The interaction between patients’ age and
any survival benefit from the RA was assessed by spline analysis.
Results:After propensity matching, the sample size consisted of 809matched pairs. In the matched group, mean
follow-up was 6.4  3.6 years (range, 0-13.6 years). Survival was 96.8%  0.6% versus 96.0%  0.6% at 1
year, 91.4% 1.1% versus 90.1% 1.0% at 5 years, and 83.2% 1.7% versus 79.4% 1.9% at 10 years for
patients receiving RA or SVG, respectively. RA use was associated with a lower risk for late death (hazard ratio
[HR], 0.75; 95% confidence interval [CI], 0.57-0.98; P ¼ .03). However, the protective effect from RA on late
survival was not equally present across all age groups, as shown by spline analysis. The survival advantage from
RAwas maximum in patients 60 years and younger (upper limit of 95% CI,<1) and gradually declined with
increasing age, until it was no longer present in patients older than 70 years (adjusted HR, 0.90; 95%
CI, 0.63-1.28; P ¼ .57).
Conclusions: The use of the radial artery graft as a second conduit improves all-cause mortality in
patients undergoing primary isolated CABG up to the age of 70 years. (J Thorac Cardiovasc Surg
2013;146:1078-85)Patients undergoing coronary artery bypass grafting
(CABG) achieve better survival rates when the left internal
thoracic artery (LITA), rather than a saphenous vein graft
(SVG), is grafted to the left anterior descending artery.1,2
As a result, several groups have been encouraged to
investigate the use of additional arterial conduits, such as
the radial artery (RA).3 After early disappointing experi-
ences,4 improved harvesting techniques, together with po-
tential benefits of calcium channel blockers,5 have led to
the RA becoming an increasingly popular conduit, as evi-
denced by improved patency and survival rates in observa-
tional cohort studies, when compared with SVG.e Department of Cardiothoracic Surgery, Papworth Hospital, Papworth
rd, Cambridge, England.
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The Journal of Thoracic and Cardiovascular SurHowever, controversy still exists about the superiority of
the RA over the SVG as a second conduit in CABG.6
Conflicting results have been reported from randomized
controlled trials, showing that the RA offers an advantage
in terms of angiographic patency at longer-term fol-
low-up.7,8 Therefore, it seems reasonable to expect the
use of RA to improve clinical outcomes and, in particular,
survival, in the younger segment of the surgical
population, with longer life expectancy. In fact,
observational studies reporting a survival advantage from
the radial artery over SVG have included relatively young
patients.9 However, whether the RA graft confers a survival
benefit over the SVG in elderly patients remains unknown.
Furthermore, the point at which ‘‘young’’ becomes ‘‘old’’ is
in continuous transition and may continue to advance as
improved public health and lifestyle changes allow people
to live longer. There is no clear guidance on arterial grafts
choice, aside from the LITA. In particular, the recommen-
dation for a liberal use of arterial grafts in younger patients,
including the RA, is not conclusive, and further evidence is
needed to provide guidance on the optimal graft choice for
CABG in various age groups.10
In the present study, we sought to investigate the presence
of any age-related benefit conferred by the use of the RA,
compared with the more conventional approach using thegery c November 2013
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
HR ¼ hazard ratio
LAD ¼ left anterior descending artery
LITA ¼ left internal thoracic artery
PS ¼ propensity score
RA ¼ radial artery
SVG ¼ saphenous vein graft
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mortality in many patients undergoing primary isolated
CABG.METHODS
The study was conducted in accordance with the principles of the
Declaration of Helsinki and approved by the institutional review committee
on human research.
We retrospectively analyzed data collected in real time in the surgical
database of Papworth Hospital, Cambridge, England, from March 1996 to
May 2012. This database is maintained by a team of full-time clinical infor-
mation analysts,who are responsible for continuous data collection as part of
a robust audit process, linked to a national database. Data collection is vali-
dated regularly. Informationabout death fromanycause is regularlyobtained
from the General Register Office approximately 1 week after the event.
Patients included in the present analysis met the following criteria: (1)
isolated first-time CABG, (2) multivessel coronary artery disease requiring
2 or more grafts to different target vessels, (3) in situ LITA grafted to the
left anterior descending artery (LAD), and (4) RA and/or SVG used to
complete revascularization. Patients receiving other arterial conduits,
such as the right internal thoracic artery or the gastroepiploic artery,
were excluded. The decision to use RA instead of SVG only to complete
revascularization was at the discretion of the consultant surgeon.
Patients who received LITA-LAD, RA as the second conduit, and SVGs
when needed formed the RA group. Patients undergoing conventional
surgical strategy, with LITA-LAD and SVGs only formed the SVG group.
The primary study end point was all-cause late death; this represents the
most robust and unbiased index event because no adjudication is required,
thus avoiding inaccurate or biased documentation and clinical assessments.
The impact of RA grafting on perioperative (within 30 days) mortality was
also investigated.
Surgical Procedures
Indications for myocardial revascularization were based on standard
clinical and angiographic criteria. All patients were operated on through a
median sternotomy. LITAs were dissected with either electrocautery as a
pedicled graft or scissors and clips without cauterization as skeletonized
conduits. RAs were harvested with the use of scissors and clips. ITAs
and RAs were stored in a diluted solution of papaverine. Most of the
operations were performed with standard cardiopulmonary bypass, with
few performed on the beating heart. Myocardial preservation during
cardiopulmonary bypass involved intermittent, antegrade crystalloid or
blood cardioplegia.
Statistical Analysis
Variables were summarized as mean SD for continuous variables and
as proportion for categorical variables in the 2 groups. Covariates included
in the analysis were as follows: age, sex, left ventricular function, presenceThe Journal of Thoracic and Carof unstable angina, critical preoperative state, preoperative renal failure,
cerebrovascular accident, diabetes while taking insulin, extracardiac
arteriopathy, chronic obstructive pulmonary disease, surgical priority,
off-pump bypass grafting, number of grafts, grafted obtuse marginal
branches, grafted right coronary artery, sequential grafts, and year of
operation. Because of the significant imbalances in baseline covariates
between groups, we used propensity score (PS) matching. A PS represent-
ing the probability of having RA as opposed to SVG only was calculated
for each patient by using a logistic regression model that identified
variables associated independently with the conduit used. Variables used
in the model are shown in Table 1. Pairs of patients with RA and SV
were derived using greedy 1:1 matching with a calipers of width 0.2 SDs
of the logit of the PS. Covariate balance was measured using the standard-
ized differences, by which an absolute standardized difference of greater
than 10% is suggested to represent meaningful covariate imbalance. A
multiphase model including early (log-linear) and late (Weibull) phases
was used to derive mortality hazard function in the matched sample. An
additional adjustment for covariates, which were still unbalanced in the
matched sample, was also used. The effect of age on survival from RA
versus SVG was then investigated. For this purpose, the hazard ratio,
with its 95% confidence interval (CI), was calculated for each quartile of
the continuous variable ‘‘age’’ using the matched sample. Then, spline
analysis (cubic method) was used to derive the hazard function across all
patient ages. P<.05 was used to indicate statistical significance. All statis-
tical analyses were performed using R, version 2.15.2 (R Foundation for
Statistical Computing, Vienna, Austria; available at: http://www.R-
project.org). The ‘‘nonrandom’’ package (available at: http://crantastic.
org/packages/nonrandom) was used.RESULTS
Study Population
A total of 16,057 patients underwent first-time isolated
CABG at Papworth Hospital during the study period.
Reasons for exclusion are listed in Figure 1.
The final study population consisted of 9005 patients.
The use of RA was recorded in 936 patients. In the
treatment (RA) group, 504 patients had total arterial
revascularization with RA grafts only used to complete
revascularization. The use of SVGs only aside from the
LITA was recorded in 8069 patients. The baseline
characteristics among the unmatched RA group and the
unmatched SVG group are summarized in Table 1.
Prematching standardized differences exceeded 10% for
10 of the 17 covariates in the RA group, when compared
with the SVG group. Patients receiving RA tended to be
younger, were more likely to be female, and were more
likely to have a reduced left ventricular function. The
use of RA was associated with more off-pump bypass
grafting procedures and sequential grafts. Finally, patients
receiving RA had surgery in the earlier years of the study
period. Patients in the SVG group were more likely to
have a critical preoperative state, previous cerebrovascular
accidents, more total grafts, and the right coronary artery
grafted.Propensity Score Matching Analysis
PS matching created a total of 809 matching sets. After
matching, all covariates were well balanced among the 2diovascular Surgery c Volume 146, Number 5 1079
TABLE 1. Baseline characteristics between the RA and SVG groups before and after matching
RA (unmatched)
(n ¼ 936)
SVG (unmatched)
(n ¼ 8069)
StDf
(before matching)
RA (matched)
(n ¼ 809)
SVG (matched)
(n ¼ 809)
StDf
(after matching)
Age, mean  SD, y 65  10 68  9 28.2 64  10 65  10 3.14
Female sex,% 20.4 18.0 33.5 22.0 19.4 9.7
LV function,% 15.3 11.6
Moderate 41.9 36.3 41.2 38.2
Poor 12.6 10.2 12.7 10.3
Unstable angina,% 8.5 6.9 5.9 7.5 8.6 4.0
Critical preoperative state,% 1.8 3.4 10.3 1.9 1.8 0.9
Renal failure,% 0.7 0.6 0.9 0.7 0.7 0
Cerebrovascular accident,% 0.2 1.6 14.6 0.2 0.4 4.0
Diabetes,% 10.2 11.5 3.1 10.1 12.1 4.1
Extracardiac arteriopathy,% 13.8 11.7 6.2 13.1 12.0 3.3
COPD,% 11.8 10.9 0.7 11.4 10.3 3.6
Surgical priority 6.8 1.0
Urgent,% 22.9 19.8 22.9 22.6
Emergent,% 3.1 3.5 3.2 2.8
OPCAB,% 37.6 2.7 96.4 27.8 25.5 5.3
No. of grafts, mean  SD 3.0  0.7 3.3  0.7 35.6 3.0  0.7 3.1  0.7 6.1
OM branches grafted,% 85.9 87.0 3.3 86.2 85.3 2.4
RCA grafted,% 72.9 80.8 18.8 73.4 74.8 3.1
Sequential grafts performed,% 27.0 13.7 99.5 24.5 20.4 9.7
Year of operation (median) 2004 2005 39.5 2004 2005 17.8
SVG, Saphenous vein graft; StDf, standardized difference; SD, standard deviation; RA, radial artery; LV, left ventricle; COPD, chronic obstructive pulmonary disease; OPCAB,
off-pump coronary artery bypass grafting; OM, obtuse marginal; RCA, right coronary artery.
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difference in left ventricular function (Table 1). Therefore,
these covariates were selected for additional adjustment in
the final model for late mortality.
In the matched sample of 809, there were 17 (2.1%) and
18 (2.2%) perioperative deaths (within 30 days) in the
RA and SVG groups, respectively (P ¼ .7). Use of the
RA did not influence operative mortality (unadjusted odds
ratio [OR], 0.75; 95% CI, 0.28-1.96) and mortality after
adjustment (adjusted OR, 1.56; 95% CI, 0.44-5.56).
Mean follow-up was 6.4  3.6 years (range, 0-13.6
years). During follow-up, 98 patients in the RA group andFIGURE 1. Study flow chart. CABG, Coronary artery bypass grafting;
NA, no information available; GEA, gastroepiploic artery; RITA, right
internal thoracic artery; LITA, left internal thoracic artery; LAD, left
anterior descending artery; RA, radial artery; SVG, saphenous vein graft.
1080 The Journal of Thoracic and Cardiovascular Sur115 patients in the SVG group died.When all matched cases
were included, survival was 96.8%  0.6% versus 96.0%
 0.6% at 1 year, 91.4% 1.1% versus 90.1% 1.0% at
5 years, and 83.2%  1.7% versus 79.4%  1.9% at
10 years for patients receiving RA or SVG, respectively.
RA was associated with a lower risk for late death
(hazard ratio [HR], 0.75; 95% CI, 0.57-0.98; P ¼ .03).
However, the protective effect from RA on late survival
was not equally present across all age groups, as shown
by spline analysis (Figure 2, Table 2); in fact, it was
maximum in patients aged 60 years or younger (upper limit
of 95% CI,<1). The survival advantage conferred by RA
use gradually declined with increasing patients’ age, and
it was no longer present beyond 70 years of age.
An age of 70 years was then considered as the cutoff
point, and it provided good discrimination for the
age-related loss of survival benefit from the RA. RA was
associated with improved survival in patients aged 70 years
and younger, with 34 of 536 deaths (expected n ¼ 46.1) in
the RA group versus 55 of 353 deaths (expected n¼ 49.2) in
the SVG group (adjusted HR, 0.57; 95% CI, 0.37-0.88;
P ¼ .01). Survival was 98.7%  0.4% versus 97.5% 
0.6% at 1 year, 95.8%  0.9% versus 94.1%  1.0% at
5 years, and 91.6%  1.4% versus 85.4%  2.0% at 10
years for patients receiving RA or SVG only, respectively.
However, RA was no longer protective for late
mortality in patients older than 70 years, with 64 of 273
deaths (expected n ¼ 65) in the RA group versus 60
of 274 deaths (expected n ¼ 59) in the SVG groupgery c November 2013
FIGURE 2. Hazard ratios (HR) and 95% confidence intervals for radial artery (RA) versus saphenous vein graft as second conduit, according to age of
patients at surgery. LL, Lower limit; UL, Upper limit.
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Survival was 93.0%  1.5% versus 93.0%  1.5% at 1
year, 82.5%  2.5% versus 81.8%  2.6% at 5 years,
and 65.3%  4.6% versus 65.5%  4.3% at 10 years for
patients receiving RA or SVG, respectively (Figure 3).Unadjusted Analysis
In the unmatched sample, early mortality (within
30 days) was 20 (2%) of 936 in the RA group and
154 (1.9%) of 8069 in the SVG group, and the use of
RA did not affect this outcome (crude OR, 1.22; 95%TABLE 2. Radial artery– versus saphenous vein graft–related hazard
ratio for late death according to patient age
Age, y Hazard ratio Lower limit Upper limit
59.00 0.07 0.008 0.58
60.86 0.18 0.039 0.81
62.73 0.29 0.07 1.04
64.60 0.42 0.13 1.28
66.46 0.57 0.21 1.50
68.33 0.74 0.31 1.72
70.20 0.92 0.44 1.92
72.06 1.09 0.56 2.09
73.93 1.21 0.66 2.21
75.80 1.29 0.72 2.27
77.66 1.33 0.76 2.29
79.53 1.34 0.77 2.27
81.40 1.32 0.77 2.21
83.26 1.27 0.75 2.14
85.13 1.22 0.72 2.04
87.00 1.15 0.68 1.94
Spline analysis (cubic method) results are given.
The Journal of Thoracic and CarCI, 0.71-1.79). Mean follow-up was 6.4  4.0 years
(range, 0-15.4 years). The use of the RA was associated
with a marginally significant risk reduction for late
mortality when patients of all ages were included in the
analysis (crude HR, 0.83; 95% CI, 0.69-0.99; P ¼ .05).
By using 70 years of age as the cutoff, the RA was
associated with better late survival in patients 70 years or
younger (crude HR, 0.62; 95% CI, 0.47-0.82; P ¼ .005),
but not in patients older than 70 years (crude HR, 1.21;
95% CI, 0.94-1.55; P ¼ .1).DISCUSSION
The data emerging from this analysis indicate that, in
patients with multivessel coronary disease undergoing first-
time CABG, the use of RA as a second conduit (in addition
to LITA-LAD) is associated with improved long-term sur-
vival, when compared with patients receiving only LITA-
LAD and only SVGs. However, this benefit is not constant
across all age groups: the survival benefit conferred by the
use of RA gradually becomes less evident with increasing
age, and it is no longer present for patients older than 70years.
The improvements in graft-harvesting techniques,
avoidance of mechanical dilation, new preservation
methods, and the use of postoperative calcium channel
blocker therapy to prevent early vasospasm led to a resur-
gence in the use of the RA as a bypass graft. This has led
the RA to emerge as an attractive and remarkably simple
alternative to the right internal thoracic artery to achieve
coronary revascularization with multiple arterial grafts.5,9
The question of whether RAs should be used routinely for
CABG has been addressed by several randomizeddiovascular Surgery c Volume 146, Number 5 1081
FIGURE 3. Survival curves for patients receiving radial artery (RA) versus saphenous vein graft (SVG) in the matched sample in patients aged 70 years and
younger and older than 70 years. adj, Adjusted.
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superiority in terms of angiographic patency.7,8 In
particular, a trend toward better patency rates of RA when
compared with SVG has been shown only in studies with
long-term follow-up.8 This finding suggests that the
survival advantage conferred by the use of RA may be
expected only in patients with a longer life expectancy.
Several studies have reported a favorable impact of an
LITA þ RA grafting strategy on intermediate to late
survival after CABG, when compared with the conventional
LITA þ SVG approach for multivessel coronary revascula-
rization.9,11 However, most of those studies included
relatively younger patients receiving RA as a second
conduit. In fact, surgeons have been often hesitant to
adopt radial arterial grafting in elderly patients, because
of the perceived unfavorable risk/benefit ratio in this age
group.
Zacharias and colleagues9 reported RA use associated
with an improved survival in a cohort of patients with a
mean age of 61 years. Tranbaugh and colleagues12 recently
concluded that RA significantly improved long-term
survival compared with using the LITA and SVG only in
a study population with a mean age of 58 years. RA grafts
were recently reported to improve survival when compared
with SVG in patients with type 2 diabetes, but not in patients
treated with insulin.13 Mean age of the diabetic population
receiving RA grafts was 61 years. These data from small
retrospective cohort studies make it difficult to derive
definitive conclusions on the impact of RA use for CABG
in elderly patients.
On the other hand, in a prospective randomized trial,
Hayward and Buxton14 found no difference in terms of
patency rate and late survival in patients older than 70 years1082 The Journal of Thoracic and Cardiovascular Surreceiving RA or SVG as a second conduit for CABG. In a
previous study, Tranbaugh and colleagues11 concluded
than RA failed to improve survival in patients older
than 65 years, but this age cutoff was arbitrarily chosen.
Furthermore, the point at which ‘‘young’’ becomes ‘‘old’’
continues to advance, and it may continue to do so, as
improved public health and lifestyle changes cause people
to live longer. As a consequence of the lack of conclusive
data regarding the effect of patients’ age on survival
associated with the use of RAs for CABG, current
guidelines do not provide any advice on this matter.10
The present analysis investigated the interaction between
RA-related survival advantage over all patient age groups.
We found that at younger than 60 years, RA was strongly
protective for late death. This benefit gradually declined,
and it was no longer present after 70 years of age. In patients
70 years and younger, the RA was associated with an
absolute risk reduction for late death of 43% at long-term
follow-up. In patients older than 70 years, the RA did not
confer any survival benefit, when compared with patients
receiving SVGs, suggesting that other risk factors play a
prominent role in affecting survival in elderly persons.
Our results provide robust evidence strengthening the
current recommendations to use the RA in the younger
segment of the surgical population.10 Furthermore, our
data provide scientific evidence for an age cutoff for the
loss of benefit from arterial grafts, as previously suggested
by investigations on bilateral internal thoracic arteries and
age-related survival benefit.15,16
Although a benefit extending into older age cannot be
formally excluded, the perceived increased technical
complexity related to the use of arterial grafts suggests
the need to use clinical judgment on the selection of graftsgery c November 2013
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suitably designed randomized controlled trials will be
available.
Muneretto and colleagues17 conducted a prospective trial
with 160 patients older than 70 years randomized to the use
of RA or SV grafts. The RA group had superior results in
terms of angiographic patency and recurrence of angina
after a mean follow-up of 16 months. The authors were
not able to assess the impact of RA on late death because
of the short follow-up and the small sample size.
However, RA grafts were used to achieve total arterial
revascularization in all cases; this aspect might partially
account for the additional clinical benefit associated with
the use of RA grafts in elderly patients.
Habib and colleagues18 recently reported that the benefit
related with the use of RA over SVG for elderly persons
may exceed that for younger patients at short-term
follow-up. This controversial conclusion might be mostly
related to the inherent bias in patients’ selection and risk
adjustment. The main difference in survival curves between
subjects who received RA or SVGs only was observed in the
early phase. This suggests a prominent role of patients’ risk
profile, rather than the late effect of the RA, on survival
differences between the 2 groups.
There are limitations to this study. This is a retrospective,
single-center study analyzing clinical outcomes during a
16-year period; thus, its conclusionsmay not be generalizable
to other experiences, populations, and current practices. Also,
despite the use of propensity score matching as one of the
most robust tools (except for a randomized controlled trial)
to compare treatment effects, this remains a retrospective
analysis with its known inherent limitations of patient
selection and treatment bias. There were many staff surgeons
operating at Papworth Hospital during the time frame of the
present study, and surgeon performance may be an unex-
plained factor that accounts for the observed results.However,
a sensitivity analysis showed that individual surgeon perfor-
mance did not affect late survival (data not reported). It could
be argued that, for older patients, the RAwas used because of
limited conduit options, as in the case of varicose saphenous
veins, but this potential bias is unlikely to affect the study
end point. As reported in the study flow chart, a significant
number of patients were excluded because of missing data.
However, basic baseline demographic characteristics (age
and sex) and the probability of late death were compared
between patients with complete data included in the final ana-
lysis and subjects who were excluded from the study sample
because of missing data on baseline covariates (data not
reported). No statistically significant differences were found
between the 2 groups, thus supporting the notion that the final
results were not significantly affected by this limitation.
We are unable to unambiguously attribute the improved
survival to RA effects, specifically its presumed enhanced
patency rates, as neither the cause of death nor graft patencyThe Journal of Thoracic and Cardata are available. Nevertheless, all-cause death is
recommended to be considered in studies investigating
results of coronary intervention as a more reliable end point
than cause-specific mortality.19 However, this is only one of
the outcomes relevant to the elderly population, and our
study has not analyzed other important effects, such as
improvement in quality of life, recurrent ischemia or
angina, or need for repeat revascularization. Furthermore,
we have no data on the severity of stenoses in the target
vessel of RA grafts, which is well known to affect its
patency because of competitive flow.6
In conclusion, the present findings show that the use of
RAs is strongly associated with improved long-term
survival in patients younger than 60 years, and this survival
benefit extends until 70 years of age. On the basis of these
data, although the choice of surgical strategy should be
individualized for each patient, the use of RA grafts for
first-time isolated CABG should be considered as the best
option in patients, at least until the age of 70 years.
The results presented in this study may help in guiding
surgical treatment of patients undergoing CABG and
have the potential to improve recent guidelines, which
recommend the use of RA regardless of patients’ age.10
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Dr Stephen Fremes (Toronto, Canada). I wish to thank the
authors for providing me with a copy of the manuscript and the
presentation in advance.
The authors have performed a single-center observational study
to evaluate whether the benefits observed with the use of radial
grafting are evident across the spectrum of patient age. Conduit
selection was according to the decision of the consultant. Late
survival from the national registry was the primary study end
point. The authors used complex, appropriate, and sophisticated
statistical analysis to minimize bias inherent in the data. The
average follow-up was 5.7 years in the propensity-matched
populations. The investigators demonstrated that there was an
overall survival advantage with radial grafting; however, this
benefit in survival was only evident in patients younger than
70 years.
There are conflicting data in the literature regarding the
appropriateness or added value of increased arterial revasculariza-
tion in older patients, and this applies to both the use of radial
arteries as well as bilateral mammary arteries. I have several
questions which I will ask one at a time.
First of all, there were over 16,000 patients initially undergoing
isolated coronary surgery at Papworth over 16 years; however, the
study population consisted of 9000 patients, and there were more
than 4000 excluded because of information lacking on the choice
of arterial conduit. So, do you think that this would differentially
affect the results of your study one way or the other?1084 The Journal of Thoracic and Cardiovascular SurDr Benedetto. Thank you for your question. The number of
missing data was equally distributed over across all study periods.
We did assess the impact of missing data on outcomes by
conducting a simple analysis on the rate of late mortality in
patients with missing data, and we found no differences between
patients with missing data and patients included in the final
analysis. This was the only tool that we had to confirm that our
conclusions are reliable, even if it is a high number of patients
with missing data. However, the final sample study is large and
allowed us to reach reliable conclusions.
Dr Fremes. Thank you. One of the potential explanations for
the observed results is bias in the selection of the second arterial
conduit by the consultant surgeon. In other words, the radial artery
may have been preferentially used in younger patients, who are
excellent revascularization candidates, but restricted in older
patients, unless there were no other options. Do the authors believe
this or other sources of bias may have explained the lack of benefit
in older patients?
Dr Benedetto. Excellent question, thank you. The nonparsimo-
nious, saturated, propensity matching used in this study tried to
minimize the effects of selection and treatment bias, a limitation
inherent in any retrospective analysis. Furthermore, it is unlikely
that surgeon’s choice of conduits may have been forced by lack
of venous conduits, as most patients received saphenous vein
grafts in addition to the radial artery graft.
We also investigated the effect of the surgeon’s experience, the
surgeon effect on the final estimates of effect of radial artery use,
but we did not find a significant effect of surgeon on late survival.
In view of the high number of surgeons involved in this analysis,
we decided to adjust it not for a single surgeon but for the year
of operation, because we found a significant relationship with
between operative mortality and year of operation. Over time,
we found a decreasing operative mortality rate. This was also
adjusted for surgeon’s experience.
Dr Fremes. A potential explanation is the notion of
competing risk, and I assume this is what you assume explains
the lack of benefit. In other words, as patients age, the risk
of death from noncardiac causes increases. So one way to
illustrate this would be to examine the cause of death in these
patients and to see if, in fact, they are dying from noncardiac
causes. Do the authors plan to examine cause-specific mortality
in these patients?
Dr Benedetto.When we investigated our data set, we observed
that we did not have reliable information about specific cause of
death, and we decided to conduct this analysis on all-cause
mortality. We are going to complete our data set, going through
the notes, and try to obtain a more complete data set, which will
include specific cause of death. However, we decided to use
all-cause mortality as the primary outcome measure for this
analysis because it is well known that all-cause death is the most
robust and unbiased index to investigate the effect of a treatment
in a retrospective study. So, we are confident that all-cause
mortality in this retrospective analysis is a more reliable index
than cardiac-specific mortality to investigate the effect of an
arterial conduit.
However, we agree with your point and we intend to complete
our data set, going through the notes to try and obtain reliable
information on specific causes of death.gery c November 2013
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DDr Fremes. Two more questions. One potential explanation
that the radial artery may be a worse conduit in older patients
compared to younger patients is perhaps due to thickening of the
radial artery or plaque. In our institution, we actually screen
older patients with a duplex scan to look for irregularities of
the radial artery as well as assessing the adequacy of ulnar
collateral circulation. What is the screening process at Papworth?
Dr Benedetto. It was mostly the Allen test before surgery, and
intraoperatively before harvesting the radial artery, we assessed the
finger saturation during temporary occlusion of the radial artery, to
confirm the finding of the Allen test. We did not conduct any
ultrasound duplex scans of the radial artery before surgery. It is
possible and reasonable that atherosclerosis of the radial artery
in patients beyond 70 years of age may be one of the causes that
affects the survival benefit from this conduit in elderly.
Dr Fremes. Lastly, based on the findings of our study, what do
the surgeons at Papworth recommend in terms of conduit selection
for their older patients?
I wish to thank the AATS for the privilege to discuss this
excellent and provocative paper.
Dr Benedetto. It is difficult to change an individual’s belief
about the choice of graft, because at the moment we have no
definitive evidence or recommendations to guide choice of grafts
other than the LITA to complete surgical revascularization.
I hope that, on the basis of these data, surgeons would consider
arterial grafts more often to complete surgical revascularization
than they do at present.
Dr Philip Hayward (Melbourne, Australia). Thank you for a
very nice talk. As you know, our randomized trial that you quoted
in your meta-analysis has not shown any survival advantage yet,
only at midterm follow-up. But I just wanted to agreewith a couple
of things that Steve Fremes said.
Analysis of the Melbourne-based database of Brian Buxton and
colleagues, with about 10,000 patients, has focused on total
arterial revascularization versus mixed grafts. We have found
differently from you, with a survival advantage in the total arterial
group which was not age dependent. However, as you suggest and
in our data set, this probably does not apply in peripheral vascular
disease. It does relate to radial quality, as Steve Fremes said, with
patients in peripheral vascular disease having probably poor
quality radials, and I suspect the older patients with peripheral
vascular disease are dying of other causes, which is why there is
no benefit.
But a nice talk, and wewill discuss it again when we finalize our
data.
Dr Benedetto. Thank you for your question. A recent paper
reporting outcomes of radial artery use in the elderly concluded
that it may be advantageous to use it even in such patients.
However, looking at the survival curves, we found that the main
difference in survival between the 2 groups is to be found inThe Journal of Thoracic and Caryounger patients. In turn, this raises a concern about the surgical
profile of patients receiving radial artery versus saphenous vein,
because the main difference in mortality is related to the younger
age at the time of surgery. So, I think that we need to conduct
robust and reliable adjusting in a retrospective analysis to be
sure that we are looking at the same main population. In a
retrospective analysis, it is generally difficult to adjust for all
factors that may affect the outcome measures under consideration,
because patients receiving radial artery may be different from
patients receiving only saphenous vein grafts. Therefore, it is
possible that some of the discordant conclusions you are referring
to may be related to selection bias.
Dr Codispoti. As the senior author on Dr Benedetto’s paper,
I rise to complete the answer to Dr Fremes’ insightful question,
related to what are the current recommendations and practice
in Papworth, in light of these data. The search for an answer to
the question of which patient is more likely to benefit from
use of the radial artery is exactly the reason why we wanted
to conduct this analysis, and we obviously stand by the solidity
of its results. Based on this, we will adopt a more coherent
strategy towards choice of the radial artery and more in general
of arterial grafts in patients younger than 70 years. We look
forward to seeing Phil Hayward’s and the Melbourne group’s
results next year.
Dr Pieter Kappetein (Rotterdam, The Netherlands). You pro-
pose a randomized trial as one of your last points in your conclu-
sion slide. If we look at the trial from David Taggart, who is
randomizing patients with 2 mammary arteries versus 1 mammary
artery, 16% of those patients that were randomized with 2 mam-
mary arteries only got 1 mammary artery graft. So, there were a
lot of crossovers, which underpowers his study tremendously.
The only thing to overcome that is to analyze it as an as-treated
population. What would be your recommendation? How would
you design a randomized trial to show that a radial artery is better
than a saphenous vein graft?
Dr Benedetto. This is a pertinent question, to which there is no
easy answer. I think that before producing a new randomized
control trial comparing the saphenous vein graft with an arterial
graft, we need to understand better and investigate the causes for
differences observed in previous randomized controlled trials
using similar outcome measures. I believe that many of the
different conclusions in respect to similar outcome measures
reached in previous trials are due to differences in their study
design. It is also possible that the different conclusions reached
by studies on similar patient populations using the same outcome
measures may be related to surgeons’ experience, or perioperative
management with calcium antagonists. Therefore, before we start
another randomized controlled trial, I think we need to better
understand why we have different conclusions from previous
randomized studies.diovascular Surgery c Volume 146, Number 5 1085
